For investors in Singapore
SUSTAINABLE INVESTMENT SOLUTIONS
Invest with Purpose for a Better Tomorrow
We believe in investing for the future, not borrowing from it.
Corporate Debt Index
The Corporate Debt Index is a study into trends in company indebtedness around the world.
Quarterly insight from our equity teams to help clients navigate the markets and opportunities ahead.
Fixed Income Perspectives
Quarterly insight from our fixed income teams to help clients navigate the markets and opportunities ahead.
Sovereign Debt Index
The Sovereign Debt Index is a long-term study into trends in government indebtedness around the world, the investment opportunities this provides and the risks it presents.
Subscribe for relevant insights delivered straight to your inbox
Given fluctuating markets, it may be prudent to sharpen the focus on sources of risk and return within one’s portfolio.
While near-term risks exist, the trajectory of emerging markets remains on stable footing
From the JHI Global Media Conference: A discussion on global efforts to reach net zero carbon emissions by 2050.
We believe active managers are in a position to drive positive change amid the shift to sustainability.
Why the push for government-negotiated drug prices could prove to be a Sisyphean task.
Natural resources companies will play a key role in the transition to a low-carbon economy.
Why we believe active engagement is key to gauging companies’ progress on addressing environmental and social issues.
A lot can happen in 30 years. Over the past three decades, we have seen explosive progress in science, technology and communications. In the same timeframe, the need for sustainable practices has become paramount. On the 30th anniversary since the origins of our Global Sustainable Equity team, we take a look at the developments that
The highly infectious variant of COVID-19 has led to rising case numbers, but we explain why a return to normalcy is still within striking distance.
The sector is experiencing its worst period of relative underperformance on record. But some of history’s biggest biotech pains have been followed by memorable gains.
Recent adjustments to tech sector regulations in China do not diminish the secular themes behind these companies’ earnings growth.
While the potential for ongoing volatility exists, we remain constructive on the prospects for growth.